As a direct measurement of unbound concentrations of drugs (C u,cell ) inside the brain parenchymal cells cannot be achieved in practice, indirect methods combining the brain slice assay and brain homogenate method have been established to estimate C u,cell (97, 104)
GLP-1/GIP
(PubMed) Aufiero E, Stitik TP, Foye PM, Chen B
Safety of Cagrinlitide and CagriSema In the obesity trial, the proportions of participants who discontinued study treatment due to adverse events were 2-6Percentage, 7Percentage, and 3Percentage in the cagrilintide, liraglutide and placebo groups, respectively [9]
6 Nevertheless, renewed interest in the therapeutic potential of GIP emerged, with studies showing that improving glycaemic control with another agent such as insulin could restore the insulinotropic potency of GIP